Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline 1Q

Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 1Q

1Q Revenues: $11.3 billion (+13%)

1Q Earnings: $2.0 billion (+19%)

Comments: Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales. Pharmaceutical sales were up 14% to $9.4 billion. Sales of Seretide/Advair rose 9% to $2.0 billion. Flovent sales were $301.0 million (+5%). Avamys/Veramyst sales increased 52% to $71.0 million. Other strong performers included Tykerb (+62% to $81.3 million), Avodart (+20% to $213.2 million), Lovaza (+9% to $164.1 million) and Arixtra (+25% to $107.4 million). Sales of Valtrex were down 46% to $270.0 million, due to generic competition. Sales of Wellbutrin dropped 67% to $30.7 million, reflecting the sale of Wellbutrin XL in the U.S. to Biovail. Restructuring charges were $462.0 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters